These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22559269)

  • 1. Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus.
    Sharma S; Lardizabal JA; Singh S; Sandhu R; Bhambi BK
    Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):152-9. PubMed ID: 22559269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial.
    Michaels AD; Appleby M; Otten MH; Dauterman K; Ports TA; Chou TM; Gibson CM
    J Invasive Cardiol; 2002 Jun; 14(6):299-302. PubMed ID: 12042618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group.
    Khan MA; Liu MW; Chio FL; Yates VB; Chapman GD; Misra VK; Sweeney A; Dean LS
    Catheter Cardiovasc Interv; 2001 Jan; 52(1):40-4. PubMed ID: 11146520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
    Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention.
    Fischell TA; Subraya RG; Ashraf K; Perry B; Haller S
    J Invasive Cardiol; 2007 Feb; 19(2):58-62. PubMed ID: 17268038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts.
    Barsness GW; Buller C; Ohman EM; Schechter E; Pucillo A; Taylor MA; Miller MJ; Reiner JS; Churchill D; Chandler AB; Gonzalez M; Smith J; Tommaso C; Berdan LG; Wildermann NM; Hasdai D; Holmes DR
    Am Heart J; 2000 May; 139(5):824-9. PubMed ID: 10783216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effect of high-dose intragraft adenosine infusion on microvascular function and prevention of no-reflow during saphenous vein grafts intervention.
    Kapoor N; Yalamanchili V; Siddiqui T; Raza S; Leesar MA
    Catheter Cardiovasc Interv; 2014 Jun; 83(7):1045-54. PubMed ID: 24307656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet IIb/IIIa antagonists followed by delayed stent implantation. A new treatment for vein graft lesions containing massive thrombus.
    Robinson N; Barakat K; Dymond D
    Heart; 1999 Apr; 81(4):434-7. PubMed ID: 10092575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distal filter protection during percutaneous coronary intervention in native coronary arteries and saphenous vein grafts in patients with acute coronary syndromes.
    Pasquetto G; Reimers B; Favero L; Saccà S; Cernetti C; Napodano M; Piccolo P; Pascotto P
    Ital Heart J; 2003 Sep; 4(9):614-9. PubMed ID: 14635379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin.
    Kaplan BM; Benzuly KH; Kinn JW; Bowers TR; Tilli FV; Grines CL; O'Neill WW; Safian RD
    Cathet Cardiovasc Diagn; 1996 Oct; 39(2):113-8. PubMed ID: 8922307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filter no reflow during percutaneous coronary interventions using the Filterwire distal protection device.
    Porto I; Choudhury RP; Pillay P; Burzotta F; Trani C; Niccoli G; Blackman DJ; Channon KM; Banning AP
    Int J Cardiol; 2006 Apr; 109(1):53-8. PubMed ID: 16084611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of 'no-reflow' complicating reperfusion therapy.
    Lee KW; Norell MS
    Acute Card Care; 2008; 10(1):5-14. PubMed ID: 18449813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world single center experience with saphenous vein grafts interventions: should filters be filtered out?
    Kassier A; Soni R; Kassab K; Kumar D; Agrawal Y; Kotaru VP; Saltiel F; Gupta V; Kalavakunta J; Fischell TA
    J Invasive Cardiol; 2023 Jul; 35(7):398-414. PubMed ID: 37769613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic intragraft injection of nicardipine prior to saphenous vein graft percutaneous intervention for the prevention of no-reflow: a review and comparison to protection devices.
    Habibzadeh MR; Thai H; Movahed MR
    J Invasive Cardiol; 2011 May; 23(5):202-6. PubMed ID: 21562350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular ultrasound findings that are predictive of no reflow after percutaneous coronary intervention for saphenous vein graft disease.
    Hong YJ; Jeong MH; Ahn Y; Kang JC; Mintz GS; Kim SW; Lee SY; Kim SY; Pichard AD; Satler LF; Waksman R; Weissman NJ
    Am J Cardiol; 2012 Jun; 109(11):1576-81. PubMed ID: 22440118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary adenosine administered during aortocoronary vein graft interventions may reduce the incidence of no-reflow phenomenon. A pilot randomised trial.
    Grygier M; Araszkiewicz A; Lesiak M; Grajek S
    Kardiol Pol; 2014; 72(2):126-33. PubMed ID: 23990233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedural results and distal embolization after saphenous vein graft stenting and angioplasty for in-stent restenosis of grafts.
    Cicek D; Doven O; Pekdemir H; Camsari A; Akkus NM; Cin GV; Parmaksiz T; Katircibasi T
    Jpn Heart J; 2004 Jul; 45(4):561-71. PubMed ID: 15353867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
    Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis.
    D'andrea C; Esposito G; Piscione F; Chiariello M
    J Cardiovasc Med (Hagerstown); 2009 Nov; 10(11):875-8. PubMed ID: 19644385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of glycoprotein IIb/IIIa inhibitors in the treatment of degenerated aortocoronary saphenous vein grafts].
    Brück M; Ludwig J; Flachskampf FA; Daniel WG
    Z Kardiol; 2002 Jan; 91(1):16-23. PubMed ID: 11963202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.